Ajinomoto Co., Ltd.

Tobishi Pharmaceutical Co., Ltd.

Ajinomoto Company Incoporated

Yoshiko Seto

Izumi Kumashiro

Shigeshi Toyoshima

Koji Fukushima

Koji Toi

Kazuhiro Kawada

Hisashi Shinkai

Syosuke Yamamura

Mikiro Fujiwara

Haruhisa Fujita

Mariko Fukuma

Mie Itoh

Munemoto Itoh

A compound of D-phenylalanine derivative for hypoglycemic use, represented by the general formula ##STR1## R.sup.1 is selected from hydrogen, alkyl of 1 to 5 carbon atoms, aryl of 6 to 12 carbon atoms, aralkyl of 6 to 12 carbon atoms, ##STR2## --CH.sub.2 CO.sub.2 R.sup.3, --CH(CH.sub.3)--OCO--R.sup.3, and --CH.sub.2 --OCO--C(CH.sub.3).sub.3 ; R.sup.2 is selected from groups comprising aryl of 6 to 12 carbon atoms, a hetero six-membered ring, a hetero five-membered ring, cycloalkyl, or cycloalkenyl, any of which groups may have one or more substituents; and R.sup.3 is selected from hydrogen and alkyl of 1 to 5 carbon atoms; the salts thereof, and precursors which can be converted thereto in the human or animal body. Some of the compounds are novel per se.

Hypoglycemic agent

The invention provides a phenylalanine derivative having the structural formula: ##STR1## and salts thereof. The derivatives and salts are useful for promoting the absorption of medicaments such as insulin.

Phenylalanine derivatives and uses thereof

An absorption promoter is disclosed which interacts with hydrophobic amino acid residues of polypeptide derivative medications and substantially increases the absorption of that medication administered orally or rectally. The promoter and medication can be compounded into unit dosages in capsule, tablet, or suppository form, or combined into elixir solutions, suspensions, etc. The absorption promoters are phenylalanine derivatives which may be prepared through conventional N-acylation techniques.

Pharmaceutical composition having an excellent absorption property

A compound represented by the formula: ##STR1## wherein R.sup.1 is a hydrogen atom, a fluorine atom, a nitro group, a hydroxyl group or a hydroxyl group protected by an esterifying group; X is CO or SO.sub.2 ; --Y-- is a straight bond, a lower alkylene group, a substituted or unsubstituted vinylene group, or group having the formula --CH.sub.2 --O-- or --O--CH.sub.2 --; R.sup.2 is a substituted or unsubstituted phenyl or naphthyl group, or R.sup.2 --Y--CO is N-benzyloxycarbonylphenylalanyl, N-benzyloxycarbonyl-4-fluorophenylalanyl or N-(m-methoxycinnamoyl)-phenylalanyl group; or a non-toxic salt thereof is disclosed along with pharmaceutical compositions containing these compounds and methods of using these compositions to increase the rate of absorption of medicines.

A process for preparing an antimalignant agent which comprises cultivating Staphylococcus epidermidis STF (Bikoken(or Microbic Industry Technological Institute)Deposit No. 3706; ATCC 31310) in a liquid culture medium, removing solid matter from the culture solution, concentrating the remaining solution, washing the precipitate thus formed with water, re-dissolving the precipitate, fractionating the solution into a number of fractions by an adsorptive filtration gel or the molecular sieve method, taking a fraction exhibiting antimalignant activity, concentrating the fraction, further purifying the fraction by ion-exchange chromatography and separating the active ingredient; and the antimalignant agent thus obtained.

Agent for inhibiting tumor induced by leukemia virus

Growing community of inventors

Funabashi, Japan

Yoshiko Seto